![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, in Combination With Tenofovir
Disoproxil Fumarate/Emtricitabine, in Previously Untreated HIV-1 Infection Through Week 96
|
|
|
Reported by Jules Levin
9th International AIDS Society (IAS) Conference on HIV Science, Paris, France, 23-26 July 2017
Pedro Cahn1; Richard Kaplan2; Paul Sax3; Kathleen Squires4; Jean-Michel
Molina5; Winai Ratanasuwan6; Mohammed Rassool7; Xia Xu8; Yan Zhou8;
Brenda Homony8; Deborah Hepler8; Hedy Teppler8; George Hanna8;
Bach-Yen Nguyen8; Wayne Greaves8; for the ONCEMRK Study Group
1Fundacion Huesped, Buenos Aires, Argentina; 2Desmond Tutu HIV Foundation, Cape Town,
South Africa; 3Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA;
4Thomas Jefferson University, Philadelphia, PA, USA; 5University of Paris Diderot, Hopital
Saint-Louis, Paris, France; 6Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok,
Thailand; 7University of Witwatersrand, Helen Joseph Hospital, Johannesburg, South Africa;
8Merck & Co., Inc., Kenilworth NJ, USA
![IAS1](../images/072417/072417-15/IAS1.gif)
![IAS2](../images/072417/072417-15/IAS2.gif)
![IAS3](../images/072417/072417-15/IAS3.gif)
![IAS4](../images/072417/072417-15/IAS4.gif)
![IAS5](../images/072417/072417-15/IAS5.gif)
![IAS6](../images/072417/072417-15/IAS6.gif)
![IAS7](../images/072417/072417-15/IAS7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|